CSF2 and HIV-1 infection: Consistently, in both donors (donors 130, Fig. 4A; and 132, Fig. 4B; dot plots and their respective bar graphs), blocking Siglec-1 significantly decreased HIV-1 infection in both GM-CSF– (P = 0.008) and M-CSF–derived MDMs (P = 0.007) by 80–97%.